Key Insights

Highlights

Treatment Research

3 treatments under study, led by Multitumor Antigen Specific Cytotoxic T Lymphocytes Tsat Directed Against Proteogenomically Determined Personalized Tumorspecific Antigens Tsa

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06193759Phase 1Recruiting

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Showing all 1 trials

Research Network

Common Treatments

  • Multitumor Antigen Specific Cytotoxic T Lymphocytes Tsat Directed Against Proteogenomically Determined Personalized Tumorspecific Antigens Tsa1
  • Group A Standardofcare Backbone Therapy1
  • Group B Salvage Backbone Therapy1

Active Sponsors

  • Children's National Research Institute1

Top Investigators

Related Conditions

  • Atypical Teratoidrhabdoid Tumor Of Cns1
  • Embryonal Tumor With Multilayered Rosettes1
  • Recurrent Ependymoma1
  • Medulloblastoma Childhood1
  • Pineoblastoma1

Activity Timeline